GKOS Stock Price, Chart, Stats & News

Glaukos Corporation
Save
8.16B
Market cap
–
Current P/E
2000.00x
Forward P/E
GKOS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 79.66% |
Operating margin | -15.40% |
Pretax margin | -38.04% |
Net margin | -36.99% |
Effective tax rate | 2.77% |
ROA | -21.01% |
ROE | -25.41% |
D/E | 0.21x |
Interest coverage ratio | -8.43x |
GKOS valuation
P/E | – |
P/S | 11.81x |
P/B | 9.04x |
P/CF | -401.21x |
P/FCF | -266.87x |
P/OCF | -401.21x |
PEG | 0.28x |
EV multiple | -40.64x |
About
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma.
Similar securities
Based on sector and market capitalization
Report issue











